Kentucky 2026 Regular Session

Kentucky House Bill HB32

Introduced
1/6/26  
Refer
1/6/26  

Caption

AN ACT relating to coverage for epinephrine devices.

Impact

The bill has the potential to significantly impact state health law by clearly defining the required coverage for epinephrine devices within health benefit plans. This would standardize coverage protocols and ensure that all individuals, regardless of the insurance provider, would have access to necessary treatment without excessive out-of-pocket costs. In addition, by capping annual cost-sharing for epinephrine devices at $100, the bill addresses concerns about affordability and access within the healthcare system.

Summary

House Bill 32 aims to ensure that all health benefit plans provide coverage for medically necessary epinephrine devices. Under this bill, at least two epinephrine devices must be covered for each insured person annually, reinforcing the importance of accessibility to life-saving treatments for those at risk of severe allergic reactions. The legislation seeks to create a clearer guideline on coverage and cost-sharing for these essential medical supplies, intending to mitigate financial barriers for individuals who need them.

Sentiment

The sentiment surrounding HB32 is generally positive, with strong support from allergy advocacy groups, health professionals, and concerned citizens. They emphasize that ensuring access to epinephrine devices could save lives and reduce the risk associated with anaphylactic reactions. However, there are concerns from some insurance providers regarding the potential financial implications of implementing these new coverage requirements, suggesting that it could lead to higher insurance premiums due to increased costs.

Contention

While the bill is predominantly supported, there are points of contention regarding its financial implications for insurers and the healthcare system at large. Critics argue that mandating coverage without sufficient analysis of potential costs could lead to increased premiums across health benefit plans, ultimately affecting all beneficiaries. Furthermore, there are discussions about whether the provisions of the bill could inadvertently conflict with federal requirements related to high-deductible health plans.

Companion Bills

No companion bills found.

Previously Filed As

KY HB236

AN ACT relating to coverage for epinephrine devices.

KY HB384

AN ACT relating to intranasal epinephrine.

KY SB93

AN ACT relating to coverage for hearing loss.

KY HB245

AN ACT relating to coverage for emergency ground ambulance services.

KY HB691

AN ACT relating to coverage for the care of children.

KY HB627

AN ACT relating to coverage for perinatal mood and anxiety disorders screenings.

KY HB540

AN ACT relating to coverage for COVID-19 testing.

KY HB683

AN ACT relating to coverage for the treatment of postpartum mood disorders.

KY SB74

AN ACT relating to coverage of annual mental health wellness examinations.

KY HB244

AN ACT relating to coverage of feeding or eating disorders.

Similar Bills

No similar bills found.